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Background: Vitamin D-binding protein (DBP) may alter the biological activity of total 25-hydroxyvitamin D [25(OH)D];
this could influence on the effects of vitamin D in relation to bone mineral density (BMD) and fractures. Emerging data
suggest that fetuin-A may be involved in bone metabolism. We aimed to investigate the influence of DBP gene
polymorphism on the relationship of vitamin D status and fetuin-A levels to BMD and bone markers.
Methods: This cross-sectional study was part of a health survey of employees of the Electricity Generating Authority
of Thailand (1,734 healthy subjects, 72% male). Fasting blood samples were assayed for 25(OH)D, fetuin-A, N-terminal
propeptides of type 1 procollagen (P1NP), C-terminal cross-linking telopeptides of type I collagen (CTx-I), and DBP
rs2282679 genotypes. L1–L4 lumbar spine and femoral BMD were measured using dual-energy X-ray absorptiometry.
Results: The DBP rs2282679 genotype distribution conformed to the Hardy–Weinberg equilibrium. There were no
correlations between 25(OH)D levels and BMD and bone markers. But a trend of positive correlation was observed for
the DBP genotypes with total hip BMD, and for the interaction between 25(OH)D and DBP genotypes with BMD at all
femoral sites. We further analyzed data according to DBP genotypes. Only in subjects with the AA (common) genotype,
25(OH)D levels were positively related to BMD and bone markers, while fetuin-A was negatively related to total hip
BMD, independently of age, gender and BMI.
Conclusions: The interaction between vitamin D status, as measured by circulating 25(OH)D and DBP rs2282679
genotypes, modified the association between 25(OH)D and BMD and bone markers. Differences in DBP genotypes
additionally influenced the correlation of fetuin-A levels with femoral BMD.
Keywords: BMD, Bone turnover markers, Fetuin-A, 25(OH)D, DBP rs2282679 genotypesBackground
Vitamin D plays important roles in bone and calcium
metabolism. It enhances intestinal calcium absorption
and suppresses bone resorption through its negative
regulatory influence on parathyroid hormone secretion
[1]. Moreover, vitamin D affects osteoblast by inhibiting
proliferation but promoting mineralization and matur-
ation [2,3]. Osteomalacia is a clinical feature of severe
vitamin D deficiency due to impaired bone mineralization* Correspondence: hataikarnn@hotmail.com
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unless otherwise stated.[4]. The influence of vitamin D on bone mass and the pro-
pensity to osteoporosis is less clear. Despite its biological
effects related to bone mass, results from clinical studies
investigating the effects of vitamin D on osteoporosis or
osteoporotic fractures have been inconsistent [5,6]. Obser-
vational studies regarding the effect of vitamin D are usu-
ally performed using circulating 25-hydroxyvitamin D [25
(OH)D], which is mostly bound to vitamin D-binding pro-
tein (DBP). It has been shown that genetic polymorphisms
of DBP, for example three major polymorphic forms
of DBP: GC1F, GC1S and GC2 are highly associated
with 25(OH)D levels[7,8]. Recently, large genome-widentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in Chinese [11,12] reported another DBP polymorph-
ism, rs2282679, had an association with vitamin D defi-
ciency. Nonetheless, data of the relationship between
DBP rs2282679 genotypes and BMD and bone markers
is scanty. It is unclear if there is an interaction of DBP
or DBP genetic polymorphism and circulating 25(OH)D
that affects bone mass; this may underlie the inconsist-
ent results of some studies.
Fetuin-A is a multifunctional protein of hepatic origin.
Besides glucose and energy homeostasis [13], fetuin-A
may be involved in bone metabolism, as suggested by re-
cent findings in elderly men and women [14,15]. With
regard to the influence of vitamin D, it has been shown
that vitamin D administration increase circulating fetuin-
A in both experimental animals [16] and humans [17].
However, the relative influence of fetuin-A versus vitamin
D and their possible interaction on bone mass is unknown
at present. Therefore, the purpose of the present study
was to investigate the influence of the interrelationship of
vitamin D status, DBP gene polymorphism and fetuin-A
levels on bone mineral density (BMD).
Methods
This study was part of a health survey of 1,734 employees
of the Electricity Generating Authority of Thailand
(EGAT). Prior to commencement, the study was ap-
proved by the Committee on Human Rights Related to
Research Involving Human Subjects, Faculty of Medi-
cine, Ramathibodi Hospital, Mahidol University; all
subjects gave written informed consent. As described in
detail elsewhere [18], survey data was collected through
self-administered questionnaires, physical examinations,
electrocardiography, chest radiography, and blood analysis.
Anthropometric variables, including weight, height and
waist circumference (WC), were measured using standard
techniques. Body mass index (BMI) was derived by weight
(kg)/height (m)2. Fasting blood samples were obtained and
assayed for 25(OH)D, fetuin-A, N-terminal propeptides
of type 1 procollagen (P1NP), C-terminal cross-linking
telopeptides of type I collagen (CTx-I), and DBP rs2282679
genotypes.
BMD
The measurement method was described in an earlier
report [19]. Each subject changed into light clothing
before undergoing BMD assessment by dual-energy X-
ray absorptiometry (DXA) at the lumbar spine (L1–L4
vertebrae) and total hip. All procedures were performed
according to the recommendations of the International
Society for Clinical Densitometry (ISCD) [20] by ISCD-
certified technologists using a Hologic QDR-4500 DXA
scanner (Bedford MA, USA). Quality assurance proce-
dures using a spine phantom were performed daily. Theprecision error was less than 1.5%. The BMD coefficients
of variation were 0.82% and 1.51% for the lumbar spine
and total hip, respectively.
DBP rs2282679 genotypes
Genomic DNA was isolated from peripheral blood leu-
kocytes using a standard phenol–chloroform extraction
method. The DBP rs2282679 polymorphism on chromo-
some 4q12-q13 was genotyped using a TaqMan® assay
with allele-specific probes on an ABI Prism® 7500 Real-
Time PCR System (Applied Biosystems, Foster City CA,
USA). These polymorphisms were chosen because of
recently large genome-wide association studies in popu-
lations of European descent reported that this genotype
had the strongest association with vitamin D deficiency
[9,10] and a similar result was reported in two studies of
Chinese people [11,12].
Fetuin-A level
Serum fetuin-A level was measured by sandwich enzyme
immunoassay (R&D Systems, Minneapolis MN, USA).
Intra- and inter-assay precisions were 4.9% and 7.3%,
respectively.
Serum 25(OH)D measurement
Serum 25(OH)D2 and 25(OH)D3 were analyzed by
LC-MS/MS with an Agilent 1200 Infinity liquid chro-
matograph (Agilent Technologies, Waldbronn, Germany)
coupled to a QTRAP® 5500 tandem mass spectrometer
(AB SCIEX, Framingham MA, USA) using a MassChrom®
25-OH-Vitamin D3/D2 diagnostics kit (ChromSystems,
Gräfelfing, Germany). The summation of serum 25(OH)
D2 and 25(OH)D3 [total 25(OH)D] was used to reflect
vitamin D status. Vitamin D deficiency was defined as
having 25(OH)D levels of less than 50 nmol/L [20 ng/mL]
[21]. The inter-assay and intra-assay coefficients of vari-
ation of total serum 25(OH)D level were 6.3% and 5.0%,
respectively.
Serum P1NP and CTx-I levels
Serum P1NP and CTx-I levels were determined by elec-
trochemiluminescence immunoassay on a Cobas e 411
analyzer (Roche Diagnostics, Mannheim, Germany).
The assays had intra-assay precision of 5.4% and 3.8%,
respectively.
Statistical analysis
Data were expressed as mean ± standard deviation (SD).
All data were normally distributed. Differences between
males and females were assessed by Student’s t-test.
Multiple linear regression analysis was performed to
identify the association between lumbar spine L1–L4
BMD, femoral neck BMD, total hip BMD, serum P1NP
and serum CTx-I (the dependent variables) and age,
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interaction between 25(OH)D and DBP genotypes [25
(OH)D ×DBP rs2282679 genotypes] and fetuin-A. Sub-
jects were then classified into three groups according to
DBP rs2282679 genotype, and the association between
all dependent variables and age, BMI, gender, 25(OH)D
and fetuin-A were reassessed by multiple linear regres-
sion analysis. The polymorphism of DBP rs2282679
genotype were assigned as the following; AA: homozy-
gous referent genotype, CA: heterozygous genotype and
CC: homozygous variant genotype. A p value less than
0.05 was considered statistically significant. All analyses
were performed using the SPSS statistical software pack-
age, version 17.0 (SPSS, Chicago IL, USA).
Results
The mean age of the subjects was 39.9 ± 6.6 years, and
most of the subjects were males (72%) due to the demo-
graphics of the EGAT workforce. A data comparison be-
tween males and females (Table 1) revealed that males
were slightly older, and had significantly higher BMI,
WC, femoral neck and total hip BMD, serum P1NP and
serum CTx-I. With regard to vitamin D status, mean
total 25(OH)D concentrations were significantly higher
in males than in females (65.20 ± 14.74 vs. 53.64 ±
12.90 nmol/L, p < 0.001; Table 1). As expected, females
had a higher prevalence of vitamin D deficiency: 41.4%
of females had 25(OH)D less than 50 nmol/L, whereas
13.6% of males were classified as vitamin D deficient.
The distribution of 25(OH)D levels in total subject, male
and female was shown in Table 2.Table 1 The clinical characteristics of the study population
Total (n = 1,734) Male (n
Age (years) 39.87 ± 6.65 40.07 ± 6
BW (kg) 66.42 ± 12.93 70.68 ± 1
BMI (kg/m2) 23.94 ± 3.76 24.59 ± 3
Waist circumference (cm) 86.11 ± 10.46 89.09 ± 9
Waist–hip ratio 0.88 ± 0.06 0.90 ± 0.
Lumbar spine (L1–L4) BMD (g/m2) 0.98 ± 0.12 0.98 ± 0.
Femoral neck BMD (g/m2) 0.80 ± 0.12 0.82 ± 0.
Total hip BMD (g/m2) 0.92 ± 0.15 0.95 ± 0.
Serum P1NP (ng/mL) 46.28 ± 18.02 48.55 ± 1
Serum CTx-I (ng/mL) 0.35 ± 0.16 0.39 ± 0.
Total 25(OH)D (nmol/L) 61.95 ± 15.17 65.20 ± 1
Subgroup stratified by 25(OH)D levels
<50 nmol/L 42.93 ± 5.82 (n = 371) 44.14 ± 4
50 to < 75 nmol/L 61.68 ± 6.67 (n = 1,051) 62.28 ± 6
≥75 nmol/L 85.45 ± 10.25 (n = 312) 85.64 ± 1
Fetuin-A (μg/mL) 559.16 ± 110.64 560.87 ±
Data is expressed as mean ± SD.The DBP rs2282679 genotype distribution conformed
to the Hardy–Weinberg equilibrium: i.e. AA (999;
57.6%), CA (637; 36.7%), and CC (98; 5.7%). Other than
25(OH)D levels, there were no differences in clinical
characteristics between subjects in each DBP genotype
of the entire cohort (combine males and females; Table 2)
or in subgroup of males or females (data not showed).
For vitamin D status, subjects with the AA genotype had
the highest 25(OH)D levels (64.6 ± 15.5 nmol/L) com-
pared with those in the CA and CC groups (59.2 ± 14.2
and 53.0 ± 10.6 nmol/L, respectively; p <0.001, Table 1).
For each DBP genotype, 25(OH)D levels in males were
higher than in females, as presented in Figure 1. 25(OH)
D levels in each DBP genotype were all significantly dif-
ferent in males (Figure 2). In female, the difference in 25
(OH)D levels were found only between those in CC vs.
AA and CA vs. AA genotype (Figure 2).
Table 3 shows the associations between BMD, serum
P1NP and serum CTx-I, and demographic parameters,
25(OH)D and fetuin-A. Age, gender and BMI were inde-
pendently associated with BMD at all skeletal sites,
as well as serum P1NP and serum CTx-I. 25(OH)D
levels were not correlated with any dependent variables,
whereas DBP genotype tended to be associated with
total hip BMD and serum P1NP (p = 0.07 and p = 0.09,
respectively). A weak correlation between fetuin-A and
total hip BMD was found (β = −0.05, p = 0.02). Since cir-
culating 25(OH)D binds to DBP, it is likely that there is
an interaction between 25(OH)D and DBP genotypes.
The femoral BMD tended to correlate to the interaction
between 25(OH)D and DBP genotypes (p = 0.09). On the= 1,246) Female (n = 488) p value (male vs. female)
.80 39.35 ± 6.23 <0.01
1.38 55.55 ± 9.92 <0.001
.54 22.27 ± 3.80 <0.001
.42 78.51 ± 9.08 <0.001
05 0.82 ± 0.06 <0.001
12 0.98 ± 0.10 NS
12 0.75 ± 0.10 <0.001
14 0.86 ± 0.15 <0.001
8.48 40.48 ± 15.35 <0.001
16 0.25 ± 0.12 <0.001
4.74 53.64 ± 12.90 <0.001
.40 (n = 169) 41.92 ± 6.63 (n = 202) <0.001
.61 (n = 790) 59.87 ± 6.55 (n = 261) <0.001
0.46 (n = 287) 83.26 ± 7.23 (n = 25) NS
110.29 554.79 ± 111.53 NS
Figure 1 25(OH)D levels in total subjects, male and female
subjects according to DBP rs2282679 genotype. The square box
represented mean ± SD. The upper and lower bar represented the
upper and lower values. **P < 0.01 for comparison of 25(OH)D levels
between male and female in CC group. ***P < 0.001 for comparison
of 25(OH)D levels between male and female in CA and AA group.
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relate to L1–L4 BMD and bone turnover markers. Sub-
group analysis in subject with 25(OH)D < 50 nmol/L
(n = 371) did not demonstrate the association between
25(OH)D levels and BMD at all skeletal sites and bone
markers (Additional file 1: Table S1).
Because of the potential interactions, data were ana-
lyzed according to DBP genotype. 25(OH)D levels were
significantly related to BMD and bone markers, inde-
pendently of age, gender and BMI – but only in subjects
with the AA genotype (Table 4C). Interestingly, fetuin-A
was significantly correlated with total hip BMD (β = −0.09,
p <0.01), and tended toward a negative correlation with
femoral neck BMD (β = −0.05, p = 0.08) in subjects with
the AA genotype (Table 3C). The correlation effect of
both 25(OH)D and fetuin-A was comparable, but in an
opposite direction, for total hip BMD, as suggested by
the standardized regression coefficients of 0.08 and −0.09,
respectively (Table 4C). The result of the correlationFigure 2 25(OH)D levels of each DBP rs2282679 genotype in total
subject, male and female. The square box represented mean ± SD.
The upper and lower bar represented the upper and lower values.
a: p < 0.05, different from CC group. b: p < 0.05, different from CA group.between 25(OH)D and BMD and bone markers in subject
with vitamin D deficiency was slightly different from the
result of the entire cohort. Multiple regression analysis
demonstrated the association between 25(OH)D levels
and serum P1NP (β = −0.18, p = 0.02) in subjects with the
CA genotype, independently of age, gender and BMI
(Additional file 1: Table S2). In subjects with the AA geno-
type, 25(OH)D levels were significantly related to L1–L4
BMD, femoral neck BMD and serum CTx (β = 0.30, p <
0.001; β = 0.15, p = 0.035 and β = -0.15, p = 0.03, respect-
ively). On the other hand, the correlation of 25(OH)D
levels and total hip BMD and serum P1NP were no longer
existed (Additional file 1: Table S2).
Discussion
The present findings demonstrated a correlation between
femoral BMD and the interaction between vitamin D sta-
tus, as measured by circulating 25(OH)D, and DBP geno-
types. It should be noted that statistical interaction does
not necessarily reflect true biological interaction. However,
a number of biological bases exist which may underlie the
observed statistical interaction.
Vitamin D metabolites are mainly transported in the
circulation by vitamin D-binding protein (DBP); that is,
about 85–90% of 25(OH)D and 1,25(OH)2D are bound
to DBP. Ten to 15% of vitamin D metabolites circulate
weakly bound to albumin, while less than 1% of circulat-
ing vitamin D is in free form [22]. Vitamin D bound to
DBP is transported within the organism, facilitating ac-
cess of vitamin D to various tissues and cell types as well
as regulating the total amount of vitamin D available for
the organism [23]. For example, at the renal proximal
tubules, megalin (a cell surface receptor for DBP) inter-
nalizes DBP-bound 25(OH)D through endocytosis, and
thus free 25(OH)D is further metabolized by renal 1α-
hydroxylase [7,24]. In addition, cubilin (another receptor
for DBP) and megalin were both detected in osteoblast-
like cell lines and human primary osteoblasts cell cul-
ture, suggesting that osteoblast are able to internalize
DBP-25(OH)D complex in vivo [2]. DBP not only acts as
a high-affinity serum transporter, but can function as a
macrophage-activating factor and actin binder. The dir-
ect effect of DBP on bone, independently of its ligands,
is not clearly understood. However, most extra-renal tis-
sues do not appear to express megalin or its associated
co-receptors, suggesting that these tissues are more likely
to acquire 25(OH)D in free form or as bio-available 25
(OH)D – i.e. the sum of the free and the albumin-bound
fraction of 25(OH)D – and not DBP-bound 25(OH)D [7].
In other words, the free and/or bio-available fraction of 25
(OH)D may be more strongly linked to biological effects
than the total form. Since only total 25(OH)D is generally
assessed in observational and interventional studies, this
may explain inconsistencies in the association of total
Table 2 The clinical characteristics of the study population stratified by DBP rs2282679 genotype
DBP genotype P value
CC (n = 98) CA (n = 637) AA (n = 999)
M/F (n,%) 69/29 (70.4/29.6) 465/172 (73/27) 712/287 (71.3/28.7) NS
Age (years) 40.08 ± 6.97 39.96 ± 6.60 39.79 ± 6.66 NS
BW (kg) 66.51 ± 12.09 66.60 ± 13.19 66.30 ± 12.84 NS
BMI (kg/m2) 23.67 ± 3.40 23.93 ± 3.82 23.97 ± 3.76 NS
WC (cm.) 86.41 ± 9.90 86.28 ± 10.80 85.98 ± 10.31 NS
WHR 0.88 ± 0.06 0.88 ± 0.07 0.88 ± 0.06 NS
Lumbar spine L1-4 BMD (g/m2) 0.98 ± 0.11 0.98 ± 0.12 0.98 ± 0.12 NS
Femoral neck BMD (g/m2) 0.80 ± 0.11 0.80 ± 0.12 0.80 ± 0.12 NS
Total hip BMD (g/m2) 0.92 ± 0.11 0.92 ± 0.13 0.92 ± 0.16 NS
Serum P1NP (ng/mL) 46.35 ± 15.20 46.22 ± 18.55 46.31 ± 17.95 NS
Serum CTx (ng/mL) 0.36 ± 0.15 0.35 ± 0.16 0.35 ± 0.16 NS
Total 25(OH)D (nmol/L) 53.0 ± 10.6 59.2 ± 14.2 64.6 ± 15.5 <0.001
Fetuin-A (μg/mL) 563.71 ± 112.35 563.01 ± 110.24 556.25 ± 110.75 NS
Data is expressed as mean ± SD.
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porting this free-hormone hypothesis, some studies
have suggested that free or bio-available 25(OH)D, as
opposed to total 25(OH)D, is more strongly correlated
with BMD [25,26].
Accumulated evidence suggests the influence of DBP
polymorphism on circulating 25(OH)D. Most studies
have investigated three major polymorphic forms of
DBP: GC1F, GC1S and GC2 (rs7041 and rs4588) [27].
These DBP variants exhibit differences in affinity to 25
(OH)D and 1,25(OH)2D, with the hierarchy of affinity
binding GC1F > GC1S > GC2 [8]. Thus, subjects with
GC1F alleles had the highest total 25(OH)D levels, while
subjects with GC2 had the lowest [28]. Recently, two
large genome-wide association studies in populations of
European descent reported that rs2282679, another DBP
polymorphism, had the strongest association with vita-
min D deficiency [9,10]. A similar result was reported in
two studies of Chinese people [11,12]. That is consistent
with the present findings, where total 25(OH)D levels inTable 3 The association between BMD, serum P1NP, serum C
genotype, 25(OH)D χ DBP rs2282679 genotype and fetuin-A b
Lumbar spine L1-L4 BMD Femo
β p β
Age -0.09 <0.001 -0.20
BMI 0.22 <0.001 0.39
Male gender -0.06 0.03 0.13
25(OH)D -0.02 NS -0.10
DBP rs2282679 genotype -0.09 NS -0.14
25(OH)D χ DBP rs2282679 genotype 0.11 NS 0.25
Fetuin-A -0.02 NS -0.02subjects who had the minor genotype (CC) were about
11 nmol/L lower than in those who had the major geno-
type (AA). We noticed that the prevalence of DBP
rs2282679 genotypes in Thais was slightly different than
those reported in Chinese [11]: i.e. AA genotype, 57% vs.
45–48%; CA genotype, 37% vs. 42–48%; and CC geno-
type, 6% vs. 10–11% (in Thais and Chinese, respectively).
Findings from in vitro studies, such as in monocytes
[29], dendritic cells [30] and keratinocytes [31], suggest
that the biological effects of vitamin D are dependent on
both the serum concentration of free 25(OH)D and the
DBP genotype. For example, monocytes exposed to 25
(OH)D showed less induction of antimicrobial cathelici-
din in the presence of DBP, while there was much more
potent induction of cathelicidin in human cell cultures
containing lower-affinity forms of DBP [29]. Similarly,
the ability of 25(OH)D to induce dendritic cells to be-
come tolerogenic regulatory T cells was found to be en-
hanced by either a lower concentration of DBP or by the
presence of lower-affinity genetic variants of DBP [30].TX and age, BMI, gender, 25(OH)D, DBP rs2282679
y multiple regression analysis
ral neck BMD Total hip BMD Serum P1NP Serum CTx-I
p β p β p β p
<0.001 -0.12 <0.001 -0.19 <0.001 -0.21 <0.001
<0.001 0.37 <0.001 -0.05 0.05 -0.08 <0.001
<0.001 0.17 <0.001 0.25 <0.001 0.44 <0.001
NS -0.11 NS 0.10 NS 0.08 NS
NS -0.17 0.07 0.17 0.09 0.13 NS
0.09 0.26 0.09 -0.25 NS -0.21 NS
NS -0.05 0.02 0.04 NS -0.01 NS
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action between 25(OH)D and DBP genotypes, we classi-
fied subjects according to DBP genotype. Our method
differed from previous studies [25,26] in that we did not as-
sess DBP levels directly and did not calculate the amounts
of free and bio-available 25(OH)D. Nevertheless, it was
found that 25(OH)D was significantly related to BMD and
bone markers, independently of age, gender and BMI – but
only in subjects with the AA genotype. The analysis in sub-
jects with vitamin D deficiency was mostly corresponded
with the result of the entire cohort. Even more the stronger
correlation between 25(OH)D levels to L1–L4 BMD, fem-
oral neck BMD and serum CTx were found (Additional
file 1: Table S2). We propose that the difference in affinity
of vitamin D ligands for DBP and the difference in amount
of free and bio-availability forms of 25(OH)D in each DBP
genotype could underlie our finding. Our study demon-
strated that 25(OH)D levels was highest in subjects in AA
genotype. Thus, the affinity of vitamin D ligands for DBP
is possibly highest in the AA genotype and lowest in the
CC genotype. It would be the case that DBP-bound 25
(OH)D of subject in AA genotype more reuptake at the
proximal tubule, provide more 25(OH)D for renal syn-
thesis of 1,25(OH)2D to facilitate circulating levels of
this hormone and support endocrine function [27], in-
cluding bone health. About free hormone hypothesis, a
study of Johnsen et al. which explored the effects ofTable 4 The association between BMD, serum P1NP, serum C
multiple regression analysis in subjects stratified by the DBP
Lumbar spine L1-L4 BMD Femoral neck BMD
β p β p
A: DBP genotype = CC (n = 98)
Age -0.13 NS -0.14 NS
BMI 0.23 0.04 0.42 <0.001
Male gender 0.05 NS 0.25 0.01
25(OH)D 0.02 NS 0.01 NS
Fetuin-A -0.07 NS -0.10 NS
B: DBP genotype = CA (n = 637)
Age -0.09 0.03 -0.21 <0.001
BMI 0.21 <0.001 0.38 <0.001
Male gender -0.03 NS 0.13 <0.01
25(OH)D 0.01 NS 0.02 NS
Fetuin-A 0.00 NS 0.04 NS
C: DBP genotype = AA (n = 999)
Age -0.08 0.01 -0.19 <0.001
BMI 0.22 <0.001 0.39 <0.001
Male gender -0.09 0.01 0.13 <0.001
25(OH)D 0.08 0.01 0.10 <0.01
Fetuin-A -0.04 NS -0.05 0.08rs7041 and rs4588 polymorphisms on BMD, reported
that the correlation of the free and bio-available forms
of 25(OH)D with bone density were stronger after
adjusting for these common polymorphisms [25].
Otherwise, to date there has been little published infor-
mation concerning the influence of DBP rs2282679
polymorphism on BMD. Measurement of DBP levels and
additional calculation for DBP-bound/free 25(OH)D in
the recent cohort are further warranted to prove this hy-
pothesis. With regard to gender, 25(OH)D of subjects with
AA genotype was independently associated with L1-L4
BMD only in females and associated with femoral neck
and total hip BMD only in males (data not showed).
Fetuin-A was also demonstrated in the present study
to be related to BMD at femoral sites. Fetuin-A is a
multifunctional protein mainly of hepatic origin, and
plays key roles in calcium and bone metabolism as well
as in glucose and energy homeostasis [32]. Fetuin-A is a
natural inhibitor of metastatic calcification [32]. How-
ever, it has been demonstrated in a number of studies
that fetuin-A is positively correlated with bone mass
[14,15]. This seemingly contradictory observation has
been reconciled by a recent study taking into account
the size-selective permeability of collagen fibrils [33].
Although the present study revealed an association be-
tween fetuin-A and BMD, the direction of the association
was the opposite of previous findings among the elderlyTX and age, BMI, gender, 25(OH)D and fetuin-A by
rs2282679 genotype
Total hip BMD Serum P1NP Serum CTx
β p β p β p
-0.15 NS -0.25 0.02 -0.20 0.04
0.51 <0.001 0.01 NS -0.07 NS
0.23 0.02 0.08 NS 0.41 <0.001
-0.05 NS 0.05 NS 0.05 NS
-0.08 NS 0.19 0.07 0.16 0.08
-0.15 <0.001 -0.15 <0.001 -0.19 <0.001
0.36 <0.001 -0.04 NS -0.07 0.06
0.20 <0.01 0.22 <0.001 0.40 <0.001
0.02 NS -0.01 NS -0.01 NS
0.03 NS 0.05 NS -0.03 NS
-0.10 <0.01 -0.21 <0.001 -0.23 <0.001
0.37 <0.001 -0.06 0.07 -0.09 0.003
0.15 <0.001 0.28 <0.001 0.46 <0.001
0.08 <0.01 -0.11 0.001 -0.10 0.002
-0.09 <0.01 0.02 NS -0.01 NS
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the differences in the present study which may account
for this anomaly is the relatively young age of the study
population. Fetuin-A apparently possesses a biphasic re-
sponse, the underlying basis of which is not entirely clear
[34]. The present study also demonstrated that the associ-
ation of fetuin-A with bone mass varied according to DBP
genotype, and that this effect was independent of vitamin
D status. This observation requires further confirmation,
however, and should be taken into account in future stud-
ies investigating the effect of fetuin-A on bone.
A number of limitations are present in our study. As
mentioned above, our study population was relatively
young, with an age range of 25–54 years. Generalizability,
if applicable, of our results is therefore limited to this par-
ticular age group. The circulating levels of vitamin D-
binding protein were not measured, and so we were not
able to determine if the interaction between the vitamin
D-binding protein gene and vitamin D status was also ap-
plicable and could be explained by variations in circulating
vitamin D-binding protein. Finally, calcium intake data
was not available in the present study.
In conclusion, in young healthy Thai adults, inter-
action between vitamin D status, as measured by circu-
lating 25(OH)D and DBP rs2282679 genotypes, modified
the association between total 25(OH)D and bone density
and bone turnover markers. Differences in DBP geno-
types additionally influenced the correlation of fetuin-A
levels with femoral sites BMD.Additional file
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